Baseline characteristics of study cohort
| . | N = 496 . |
|---|---|
| Age at diagnosis, median (IQR) | 53 (44-62) |
| Male sex, n (%) | 289 (58%) |
| Race/ethnicity, n (%) | |
| Non-Hispanic White | 68 (14%) |
| Non-Hispanic Black | 97 (20%) |
| Hispanic | 297 (60%) |
| Asian and Pacific Islander | 33 (6.7%) |
| Preferred language, n (%) | |
| English | 253 (51%) |
| Spanish | 223 (45%) |
| Other/unknown | 20 (4.0%) |
| Insurance status, n (%) | |
| Private | 26 (5.2%) |
| Medicare | 24 (4.8%) |
| Medicaid | 72 (15%) |
| Uninsured | 373 (75%) |
| ADI national quartile, n (%) | |
| 1 | 34 (6.9%) |
| 2 | 60 (12%) |
| 3 | 180 (37%) |
| 4 | 217 (44%) |
| Histology, n (%) | |
| DLBCL, NOS, germinal center | 184 (37%) |
| DLBCL, NOS, nongerminal center | 172 (35%) |
| DLBCL, NOS, unclassifiable | 57 (11%) |
| PBL | 27 (5.4%) |
| DLBCL/HGBCL with MYC/BCL2 rearrangements | 16 (3.2%) |
| Primary mediastinal LBCL | 15 (3.0%) |
| T-cell/histiocyte-rich LBCL | 10 (2.0%) |
| PEL | 6 (11.2%) |
| Mediastinal gray zone lymphoma | 5 (1.0%) |
| Intravascular LBCL | 3 (0.6%) |
| Primary cutaneous DLBCL | 1 (0.2%) |
| Stage, n (%) | |
| Early stage (I-II) | 156 (31%) |
| Advanced stage (III-IV) | 340 (69%) |
| ECOG PS, n (%) | |
| 0-1 | 232 (47%) |
| 2-4 | 126 (25%) |
| Unknown | 138 (28%) |
| R-IPI risk group, n (%) | |
| Very good | 68 (14%) |
| Good | 206 (42%) |
| Poor | 215 (44%) |
| History of HIV infection, n (%) | 82 (17%) |
| NCI-CI, median (IQR) | 0.00 (0.00-0.58) |
| Hemoglobin, median (IQR), g/dL | 11.80 (9.88-13.20) |
| Serum creatinine, median (IQR), mg/dL | 0.80 (0.70-1.00) |
| Serum albumin, median (IQR), g/dL | 3.40 (2.90-3.80) |
| INR, median (IQR) | 1.10 (1.00-1.20) |
| Serum LDH (× ULN), median (IQR) | 1.22 (0.82-2.16) |
| PNI, median (IQR) | 40 (33-47) |
| . | N = 496 . |
|---|---|
| Age at diagnosis, median (IQR) | 53 (44-62) |
| Male sex, n (%) | 289 (58%) |
| Race/ethnicity, n (%) | |
| Non-Hispanic White | 68 (14%) |
| Non-Hispanic Black | 97 (20%) |
| Hispanic | 297 (60%) |
| Asian and Pacific Islander | 33 (6.7%) |
| Preferred language, n (%) | |
| English | 253 (51%) |
| Spanish | 223 (45%) |
| Other/unknown | 20 (4.0%) |
| Insurance status, n (%) | |
| Private | 26 (5.2%) |
| Medicare | 24 (4.8%) |
| Medicaid | 72 (15%) |
| Uninsured | 373 (75%) |
| ADI national quartile, n (%) | |
| 1 | 34 (6.9%) |
| 2 | 60 (12%) |
| 3 | 180 (37%) |
| 4 | 217 (44%) |
| Histology, n (%) | |
| DLBCL, NOS, germinal center | 184 (37%) |
| DLBCL, NOS, nongerminal center | 172 (35%) |
| DLBCL, NOS, unclassifiable | 57 (11%) |
| PBL | 27 (5.4%) |
| DLBCL/HGBCL with MYC/BCL2 rearrangements | 16 (3.2%) |
| Primary mediastinal LBCL | 15 (3.0%) |
| T-cell/histiocyte-rich LBCL | 10 (2.0%) |
| PEL | 6 (11.2%) |
| Mediastinal gray zone lymphoma | 5 (1.0%) |
| Intravascular LBCL | 3 (0.6%) |
| Primary cutaneous DLBCL | 1 (0.2%) |
| Stage, n (%) | |
| Early stage (I-II) | 156 (31%) |
| Advanced stage (III-IV) | 340 (69%) |
| ECOG PS, n (%) | |
| 0-1 | 232 (47%) |
| 2-4 | 126 (25%) |
| Unknown | 138 (28%) |
| R-IPI risk group, n (%) | |
| Very good | 68 (14%) |
| Good | 206 (42%) |
| Poor | 215 (44%) |
| History of HIV infection, n (%) | 82 (17%) |
| NCI-CI, median (IQR) | 0.00 (0.00-0.58) |
| Hemoglobin, median (IQR), g/dL | 11.80 (9.88-13.20) |
| Serum creatinine, median (IQR), mg/dL | 0.80 (0.70-1.00) |
| Serum albumin, median (IQR), g/dL | 3.40 (2.90-3.80) |
| INR, median (IQR) | 1.10 (1.00-1.20) |
| Serum LDH (× ULN), median (IQR) | 1.22 (0.82-2.16) |
| PNI, median (IQR) | 40 (33-47) |
IQR, interquartile range; LDH: lactate dehydrogenase; NOS: not otherwise specified; ULN: upper limit of normal.